Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis

3 Feb 2025

Abstract excerpt

Murine double minute 2 (MDM2) inhibitors have shown promising activity in TP53-wild type tumors and are under active investigation across a spectrum of malignancies. Herein, we report a 51-year-old female with MDM2-amplified, TP53-wild type adenoid cystic carcinoma who was treated with a MDM2 inhibitor and developed persistent pancytopenia despite drug discontinuation. Her pancytopenia was associated with 20...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39900989
DOI: 10.1038/s41698-025-00823-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesisPMID 39900989Read ↗

Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlinSemantic proximity Read ↗

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis.Semantic proximity Read ↗

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition.Semantic proximity Read ↗

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma.Semantic proximity Read ↗

Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.Semantic proximity Read ↗

Characterization of a novel TPMT mutation associated with azathioprine-induced myelosuppression.Semantic proximity Read ↗

TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignanciesSemantic proximity Read ↗

The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.